Air and soul: The science and application of aerosol therapy

Respiratory Care

Volumn 55, Issue 7, 2010, Pages 911-921

  Rubin, Bruce K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Asthma; Dry powder inhalers; Jet nebulizers; Pressurized metered dose inhalers

Indexed keywords

ACETYLCYSTEINE; AZTREONAM; CYCLOSPORIN; DORNASE ALFA; ERGOTAMINE; GLUTATHIONE; ILOPROST; INFLUENZA VACCINE; MANNITOL; MORPHINE; PROSTACYCLIN; TACROLIMUS; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

AEROSOL; ASTHMA; CONFERENCE PAPER; COUGHING; CYSTIC FIBROSIS; DRY POWDER INHALER; DYSPNEA; GENE THERAPY; GENE TRANSFER; INFLUENZA; INHALATIONAL DRUG ADMINISTRATION; INHALER; JET NEBULIZER; MEDICAL NEBULIZER; METERED DOSE INHALER; MIGRAINE; MINIMUM INHIBITORY CONCENTRATION; POWDER INHALER; PULMONARY HYPERTENSION; RESPIRATORY THERAPIST; VALVED HOLDING CHAMBER; HUMAN; LUNG DISEASE; NEBULIZER; PARTICLE SIZE; PATIENT COMPLIANCE; REVIEW;

ADMINISTRATION, INHALATION; AEROSOLS; HUMANS; LUNG DISEASES; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PATIENT COMPLIANCE;

EID: 77955492046     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (72)

1. Elliott HL, Reid JL. The clinical pharmacology of a herbal asthma cigarette. Br J Clin Pharmacol 1980;10(5):487-490.
2. Anonymous. Mudge inhaler. http://www.inhalatorium.com/page57.html. Accessed May 10, 2010.
3. Thiel CG. From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation. In: Dalby RN, Byron P, Farr SY, editors. Respiratory Drug Delivery V. Buffalo Grove: Interpharm Press; 1996:115-123.
4. Rau JL. The inhalation of drugs: advantages and problems. Respir Care 2005;200:50(8):367-382.
5. Weilacher RR. AARC: 50 years of service. http://www.aarc.org/member- services/history.html. Accessed May 10, 2010.
6. Rubin BK, Kelly HW. The impact of drug delivery devices in asthma management. J Respir Dis 2002;4(Suppl):S36-S43.
7. Rubin BK, Fink JB. Aerosol therapy for children. Respir Care Clinics N Am 2001;7(2):175-213.
8. Rodrigo C, Rodrigo G. Salbutamol treatment of acute severe asthma in the ED: MDI versus hand-held nebulizer. Am J Emerg Med 1998;16(7):637-642.
9. Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care 2005;50(10):1360-1375.
10. Iles R, Lister P, Edmunds AT. Crying significantly reduces absorption of aerosolised drug in infants. Arch Dis Child 1999;81(2):163-165.
11. Murakami G, Igarashi T, Adachi Y, Matsuno M, Adachi Y, Sawai M, et al. Measurement of bronchial hyperreactivity in infants and preschool children using a new method. Ann Allergy 1990;64(4):383-387.
12. Rubin BK. Bye-bye, blow-by (editorial). Respir Care 2007;52(8):981.
13. Everard ML, Clark AR, Milner AD. Drug delivery from jet nebulisers. Arch Dis Child 1992;67(5):586-591.
14. Lowenthal D, Kattan M. Facemasks versus mouthpieces for aerosol treatment of asthmatic children. Pediatr Pulmonol 1992;14(3):192-196.
15. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005;127(1):335-371.
16. Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. Medication nebulizer performance: effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996;110(2):498-505.
17. Rubin BK. Nebulizer therapy for children: the device-patient interface. Respir Care 2002;47(11):1314-1319.
18. Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2006(2);CD000052.
19. Takizawa H. Recent development of drug delivery systems for the treatment of asthma and related disorders. Recent Pat Inflamm Allergy Drug Discov 2009;3(3):232-239.
20. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002;47(12):1406-1416.
21. Pederson S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate on the effect of a Turbuhaler. Arch Dis Child 1990;65(3):308-310.
22. Meakin BJ, Cainey J, Woodcock PM. Effect of exposure to humidity on terbutaline delivery from turbohaler dry powder inhalation devices. Eur Respir J 1993;6(5):760-761.
23. Rubin BK, Fink JB. Optimizing aerosol delivery by pressurized metered dose inhalers. Respir Care 2005;50(9):1191-1197.
24. Amirav I, Newhouse MT. Aerosol therapy with valved holding chambers in young children: importance of the facemask seal. Pediatrics 2001;108(2):389-394.
25. Shah SA, Berlinski AB, Rubin BK. Force-dependent static dead space of face masks used with holding chambers. Respir Care 2006;51(2):140-144.
26. Mitchell JP, Coppolo DP, Nagel MW. Electrostatics and inhaled medications: influence on delivery via pressurized metered-dose inhalers and add-on devices. Respir Care 2007;52(3):283-300.
27. Rubin BK, Durotoye L. How do patients determine that their metered-dose inhaler is empty? Chest 2004;126(4):1134-1137.
28. Montreal Protocol, September 16, 1987, S Treaty Document 10, 100th Congress, 1st session, 26 ILM 1541.
29. Leach CL. The CFC to HFA transition and its impact on pulmonary drug development. Respir Care 2005;50(9):1201-1208.
30. Rubin BK. Inhaled corticosteroids: devices and deposition. Paediatr Respir Rev 2004;5(Suppl A):S103-S106.
31. Lasserson TJ, Cates CK, Jones AB, Steele EH, White J. Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children. Cochrane Database Syst Rev 2006;(2):CD005309.
32. Rubin BK. Mucolytics, expectorants, and mucokinetic medications. Respir Care 2007;52(7):859-865.
33. Voynow JA, Rubin BK. Mucus, mucins, and sputum. Chest 2009;135(2):505-512.
34. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005;365(9470):1552-1560.
35. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;(3):CD001287.
36. Stafanger G, Koch C. N-acetylcysteine in cystic fibrosis and Pseudomonas aeruginosa infection: clinical score, spirometry and ciliary motility. Eur Respir J 1989;2(3):234-237.
37. Henke M, Renner A, Huber RM, Seeds MC, Rubin BK. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 2004;31(1):86-91.
38. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al; Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331(10):637-642.
39. Rubin BK, Kater AP, Goldstein AL. Thymosin β4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro. Chest 2006;130(5):1433-1440.
40. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354(3):229-240.
41. Wills PJ. Inhaled mannitol in cystic fibrosis. Expert Opin Invest Drugs 2007;16(7):1121-1126.
42. Kishioka C, Okamoto K, Kim J-S. Rubin BK. Hyperosmolar solutions stimulate mucus secretion in the ferret trachea. Chest 2003;124(1):306-313.
43. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001;358(9290):1316-1321.
44. Rubin BK. Who will benefit from DNase? Pediatr Pulmonol 1999;27(1):3-4.
45. Hagerman JK, Hancock KE, Klepser ME. Aerosolised antibiotics: a critical appraisal of their use. Expert Opin Drug Deliv 2006;3(1):71-86.
46. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al; Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340(1):23-30.
47. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009;135(5):1223-1232.
48. Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 2008;21(1):71-76.
49. MacIntyre N, Rubin BK. Should aerosolized antibiotics be used for the prevention and therapy of ventilator associated pneumonia in patients who do not have cystic fibrosis? Respir Care 2007;52(4):416-422.
50. Gaensslen M. [Uber inhalation von Insulin.] Klin Wochenschr 1925;2:71-72. Article in German.
51. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005;50(9):1161-1176.
52. Rubin BK. Experimental macromolecular aerosol therapy. Respir Care 2000;45(6):684-694.
53. Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med Pulm Drug Deliv 2008;21(1):1-12.
54. Smith DJ, Bot S, Dellamary L, Bot A. Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine 2003;21(21-22):2805-2812.
55. Bennett JV, Fernandez de Castro J, Valdespino-Gomez JL, Garcia-Garcia Mde L, Islas-Romero R, Echaniz-Aviles G, et al. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull World Health Org 2002;80(10):806-812.
56. Brand P, Schulte M, Wencker M, Herpich CH, Klein G, Hanna K, Meyer T. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur Respir J 2009;34(2):354-360.
57. Snyder AH, McPherson ME, Hunt JF, Johnson M, Stamler JS, Gaston B. Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis. Am J Respir Crit Care Med 2002;165(7):922-926.
58. Eynott PR, Salmon M, Huang TJ, Oates T, Nicklin PL, Chung KF. Effects of cyclosporine A and a rapamycin derivative (SAR943) on chronic allergic inflammation in sensitized rats. Immunology 2003;109(3):461-467.
59. Groves S, Galazka M, Johnson B, Corcoran T, Verceles A, Britt E, et al. Inhaled cyclosporine and pulmonary function in lung transplant recipients. J Aerosol Med Pulm Drug Deliv 2010;23(1):31-39.
60. Brown SJ, Eichner SF, Jones JR. Nebulized morphine for relief of dyspnea due to chronic lung disease. Ann Pharmacother 2005;39(6):1088-1092.
61. Armer TA, Shrewsbury SB, Newman SP, Pitcairn G, Ramadan N. Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Curr Med Res Opin 2007;23(12):3177-3187.
62. Burkett JS. The use of the nicotine inhaler in smoking cessation. J Am Acad Nurse Pract 2006;18(3):83-91.
63. Gautam A, Waldrep JC, Densmore CL. Aerosol gene therapy. Mol Biotechnol 2003;23(1):51-60.
64. Pringle IA, Hyde SC, Gill DR. Non-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects. Expert Opin Biol Ther 2009;9(8):991-1003.
65. Rochat T, Morris MA. Gene therapy for cystic fibrosis by means of aerosol. J Aerosol Med 2002;15(2):229-235.
66. Anhoj J, Thorsson L, Bisgaard H. Lung deposition of inhaled drugs increases with age. Am J Respir Crit Care Med 2000;162(5):1819-1822.
67. Wildhaber JH, Devadason SG, Wilson JM, Roller C, Lagana T, Borgström L, LeSouëf PN. Lung deposition of budesonide from turbuhaler in asthmatic children. Eur J Pediatr 1998;157(12):1017-1022.
68. Devadason SG, Everard ML, MacEarlan C, Roller C, Summers QA, Swift P, Borgstrom L, Le Souëf PN. Lung deposition from the Turbuhaler in children with cystic fibrosis. Eur Respir J 1997;10(9):2023-2028.
69. Wildhaber JH, Janssens HM, Piérart F, Dore ND, Devadason SG, LeSouëf PN. High percentage lung delivery in children from detergent-treated spacers. Pediatr Pulmonol 2000;29(5):389-393.
70. Rubin BK. What does it mean when a patient says, "My asthma medication isn't working"? Chest 2004;126(3):972-981.
71. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343(5):332-336.
72. Rubin BK. Adherence to asthma therapy: the "blocked receptor". Pediatr Pulmonol 2004;26(Suppl):36-37.